Companies · Biotechnology

Stealth BioTherapeutics Corp

GRAND CAYMAN · Biotechnology

Diligence memoA one-page analyst read on Stealth BioTherapeutics Corp — recommendation, valuation, rhythm, risks.
$35.0M
Total raised · real
2
Rounds
1.3×
Latest step-up
Top 24%
Sector rank · raised
Series B
Latest stage · inferred · Fri Apr 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Stealth BioTherapeutics Corp looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.29× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
  • Within the normal band (129% of peer median) for its niche.
Dormant
  • Last raise 6.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Stealth BioTherapeutics Corp is one of 4293 Biotechnology companies tracked from GRAND CAYMAN. By capital raised it ranks in the upper tier (ahead of 77% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2020-04-10
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2019-10-10 Raised $15M (real) Modeled valuation $542M (est)$15M$542MSeries A2019Series B · 2020-04-10 Raised $20M (real) Modeled valuation $794M (est)$20M$794MSeries B2020+$20MCumulative $35M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$15.0M · 2019
Series B$20.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$793.8M
Base estimate est.
$40.0M
Conservative case
$3.1B
Upside case
$111.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $542.3M · 2019-10-102019Series B · modeled $793.8M · 2020-04-102020
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
6.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$69.9M/yr
Capital velocity
6.7 yr
On record since
2019
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.9× above median
This company$35.0M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.1× above median
This company$20.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 12× above median
This company$793.8M
Sector median$64.2M

Raised more than 77% of sector peers (real $). Modeled value above 87% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #32 of 118.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Pandion Therapeutics Holdco LLC · Series B Raised $40.0M · modeled $1.6B (est)Ocular Therapeutix, Inc · Series B Raised $81.0M · modeled $1.5B (est)Insilico Medicine Cayman TopCo · Series B Raised $36.8M · modeled $1.5B (est)Purigen Biosystems, Inc. · Series B Raised $61.9M · modeled $1.4B (est)Lucira Health, Inc. · Series B Raised $32.5M · modeled $1.3B (est)Peptilogics, Inc. · Series B Raised $40.9M · modeled $1.2B (est)Nanotech Energy, Inc. · Series B Raised $31.6M · modeled $1.1B (est)Windtree Therapeutics Inc /De/ · Series B Raised $104.5M · modeled $1.0B (est)Liminal BioSciences Inc. · Series B Raised $67.1M · modeled $1.0B (est)Palladio Biosciences, Inc. · Series B Raised $28.0M · modeled $1.0B (est)Faze Medicines, Inc. · Series B Raised $30.4M · modeled $999.5M (est)Inivata Ltd · Series B Raised $25.0M · modeled $992.2M (est)Stealth BioTherapeutics Corp (this company) Raised $35.0M · modeled $793.8M (est)Stealth BioTherapeutics Corp
CompanyStageRaised · realValue · estvs peer med.
Pandion Therapeutics Holdco LLCSeries B$40.0M$1.6B2.58×
Ocular Therapeutix, IncSeries B$81.0M$1.5B2.42×
Insilico Medicine Cayman TopCoSeries B$36.8M$1.5B2.37×
Purigen Biosystems, Inc.Series B$61.9M$1.4B2.22×
Lucira Health, Inc.Series B$32.5M$1.3B2.10×
Peptilogics, Inc.Series B$40.9M$1.2B1.90×
Nanotech Energy, Inc.Series B$31.6M$1.1B1.82×
Windtree Therapeutics Inc /De/Series B$104.5M$1.0B1.70×
Liminal BioSciences Inc.Series B$67.1M$1.0B1.67×
Palladio Biosciences, Inc.Series B$28.0M$1.0B1.63×
Faze Medicines, Inc.Series B$30.4M$999.5M1.62×
Inivata LtdSeries B$25.0M$992.2M1.61×
Stealth BioTherapeutics Corp this companySeries B$35.0M$793.8M1.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$15.0M2019-10-10$68.2M$542.3M90%
Series B$20.0M2020-04-10$111.1M$793.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$15.0M2019-10-10
    • First recorded raise — entered as Series A.
    • 1 investor on this round.
  2. Series B$20.0M2020-04-10
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2020 ~Q4
Modeled next raise · ~6mo cadence
$26.7M
Modeled next size est.range $20.0M$42.7M
1.3×
Last step-up
$69.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gerald Chan12 other2019-10
Francis Chen2 other2019-10
Lu Huang1 other2019-10
Edward Owens2019-10
Irene McCarthy2019-10
Kevin McLaughlin2019-10
Lou Lange2019-10
Registry & provenance

Stealth BioTherapeutics Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1696396
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cavion, Inc.BiotechnologySeries B$35.2M$885.6Msame sector · same stage
Synthorx, Inc.BiotechnologySeries B$34.7M$1.1Bsame sector · same stage
Bonti, Inc.BiotechnologySeries B$36.0M$613.7Msame sector · same stage
Loxo Oncology, Inc.BiotechnologySeries B$33.9M$948.1Msame sector · same stage
NeuroTherapeutics Pharma, Inc.BiotechnologySeries B$33.7M$476.3Msame sector · same stage
Mistral Therapeutics, Inc.BiotechnologySeries B$36.4M$1.0Bsame sector · same stage
BELLUS Health Inc.BiotechnologySeries B$33.6M$951.4Msame sector · same stage
CytoImmune Therapeutics, Inc.BiotechnologySeries B$36.5M$921.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Stealth Therapeutics, Inc.BiotechnologySeed$6.2M91%
Biocurity Pharmaceuticals Inc.BiotechnologySeed$13.3M87%
Reveal Biosensors, Inc.BiotechnologyPre-Seed$12.4M87%
Biosceptre International LtdBiotechnologyPre-Seed$13.1M87%
Revelar Biotherapeutics, Inc.BiotechnologySeries B$20.0M87%
Arcutis Biotherapeutics, Inc.BiotechnologySeries C$3.9B87%
XenoTherapeutics CorpBiotechnologySeed$39.0M86%
Eleven Biotherapeutics, Inc.BiotechnologySeries B$39.5M86%
Frequently asked
How much funding has Stealth BioTherapeutics Corp raised?
Stealth BioTherapeutics Corp has raised approximately $35.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Stealth BioTherapeutics Corp's estimated valuation?
Provath's modeled valuation for Stealth BioTherapeutics Corp is approximately $793.8M (modeled range $40.0M–$3.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Stealth BioTherapeutics Corp at?
Stealth BioTherapeutics Corp's latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Apr 10.
What does Stealth BioTherapeutics Corp do and where is it based?
Stealth BioTherapeutics Corp operates in the Biotechnology sector, based in GRAND CAYMAN.
Explore related

See where Stealth BioTherapeutics Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Stealth BioTherapeutics Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.